BioStem (BSEM) CFO Brandon Poe Exercises Options — 1,694 Shares

What Happened Brandon Poe, Chief Financial Officer of BioStem Technologies (BSEM), reported exercising or converting 1,694 derivative instruments (transaction code M) on September 15, 2026 and a simultaneous disposition of 1,694 derivative-derived shares the same day. Both the acquisition and disposition are reported at $0.00 per share (total $0 reported).

Key Details

• Transaction date: 2026-09-15 (reported on Form 4 filed 2026-09-17 — timely within Section 16 reporting rules).
• Transactions: Exercise/conversion of 1,694 derivatives (code M) at $0.00; simultaneous disposition of 1,694 derivative shares at $0.00.
• Shares owned after transaction: Not specified in the information provided in your summary.
• Footnotes in the filing: multiple vesting schedules and RSU rules are noted (e.g., RSUs represent a contingent right to one share; certain options/RSUs vest 33% at anniversary dates with the remainder vesting quarterly over subsequent two years).
• No cash value or sale proceeds are shown on the Form 4 for these entries.

Context

• Code M indicates an exercise or conversion of derivative securities (options/RSUs). Reporting $0 often means this was a conversion, net-settlement, or internal transfer rather than an open-market cash purchase or sale; it does not show market sale proceeds. The filing does not disclose an open-market sale for cash.
• The filing’s footnotes outline vesting schedules for options and restricted stock units, which explains when derivative rights become exercisable or convertible into shares.